Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

Medicine and Dentistry

• Cancer 100%
• T Cell 100%
• Chimeric Antigen Receptor T-Cell Immunotherapy 100%
• Tumor Progression 50%
• In Vitro 25%
• Monoclonal Antibody 25%
• Tumor Necrosis Factor 25%
• Secretion (Process) 25%
• B Cell 25%
• Lymphoma Cell 25%
• T-Cell Lymphoma 25%
• Leukemia 25%
• T-Cell Lymphoma Cell Line 25%
• T-Cell Leukemia Cell Line 25%
• Target Cell 25%
• Chimeric Antigen Receptor T-Cell 25%
• Single Chain Fragment Variable Antibody 25%

Immunology and Microbiology

• T Cell 100%
• Chimeric Antigen Receptor T-Cell Therapy 100%
• CD28 50%
• Monoclonal Antibody 25%
• Mouse Model 25%
• Tumor Necrosis Factor 25%
• B Cell 25%
• Secretion (Process) 25%
• Target Cell 25%
• CD69 25%
• CD19 25%
• Chimeric Antigen Receptor T-Cell 25%
• Single-Chain Variable Fragment 25%
• Lymphoma Cell 25%
• T-Cell Lymphoma Cell Line 25%
• T-Cell Leukemia Cell Line 25%
• Interleukin 8 25%

Keyphrases

• Chimeric Antigen Receptor T-cell Therapy 100%
• T-cell Malignancies 100%
• CD26 100%
• Tumor Growth 16%
• T-cell Lymphoma 16%
• Lymphoma Cells 16%
• CD28 16%
• YS110 16%
• Monoclonal Antibody 8%
• Interleukin-8 8%
• In Vivo Model 8%
• Third Generation 8%
• Clinical Practice 8%
• Overexpressing 8%
• Interferon-γ 8%
• In Vitro Study 8%
• Treatment Modalities 8%
• Survival Benefit 8%
• Highly Effective 8%
• Cell-derived 8%
• Promising Treatment 8%
• 4-1BB 8%
• Activation Markers 8%
• CD19 8%
• CD69 8%
• Dissemination Model 8%
• T-cell Leukemia 8%
• Systemic Dissemination 8%
• Leukemia Cell Lines 8%
• Anti-leukemia 8%
• B-cell Malignancies 8%
• Nascent Stage 8%
• Chimeric Antigen Receptor T Cells (CAR-T) 8%
• Single-chain Variable Fragment 8%